Abstract
Cancer therapy has been shifting away from “one-size-fits-all” approaches to treatment decisions that are predicated on the molecular profile of the patient’s cancer. Personalized medicine, precision medicine, precision oncology, or “omics-guided” therapy are expressions used for this paradigm shift often interchangeably. The uptake of precision medicine, while advancing in cancer care, has faced several adoption challenges, including education, policy, and practical factors. Facilitating the transformation toward personalized medicine that will improve patient outcomes in the oncology setting requires a coordinated effort among policymakers, cancer agencies, health systems, and industry. To implement precision medicine effectively in cancer practice requires an informatics solution beyond the legacy electronic medical record platforms currently available to clinical teams.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ashbury FD (2021) Covid-19 and supportive cancer care: key issues and opportunities. Curr Opin Oncol 33(4):295–300
Ashbury FD, Thompson K, Williams C, Williams K (2021) Challenges adopting next-generation sequencing in community oncology practice. Curr Opin Oncol 33(5):507–512
Bernstam EV, Warner JL, Krauss JC, Ambinder E, Rubinstein WS, Komatsoulis G, Miller RS, Chen JL (2022) Quantitating and assessing interoperability between electronic health records. JAMIA 29(5):753–760
Bronfenbrenner U (1977) Experimental toward an ecology of human development. Am Psychol 32:513–531. https://doi.org/10.1037/0003-066X.32.7.513
Bustillos H, Indorf A, Alwan L, Thompson J, Jung L (2022) Xerostomia: an immunotherapy-related adverse effect in cancer patients. Supp Care Cancer 30:1681–1687
Cannon C (2018) Telehealth, mobile applications, and wearable devices are expanding cancer care beyond walls. Sem Oncol Nursing 34(2):118–125
Challinor JM, Alqudimat MR, Teixeira TOA, Oldenmenger WH (2020) Oncology nursing workforce: challenges, solutions, and future strategies. Lancet Oncol 21(12):e564–e574
Chan A, Ashbury FD, Fitch MI, Koczwara B, Chan RJ (2020) Cancer survivorship care during COVID-19—perspectives and recommendations from the MASCC Survivorship Study Group. Support Care Cancer 28(8):3485–3488
Chua IS, Gaziel-Yablowitz M, Korach AT, Kehl KL, Levitan NA, Arriaga YE, Jackson GP, Bates DW, Hassett (2021) Artificial intelligence in oncology: path to implementation. Cancer Med 10(12):4138–4149
Clarke CN (2022) Disparities in creating a diverse surgical oncology physician workforce: just a leaky pipeline? Surg Oncol Clinics 31(1):21–27
Coschi CH, Juergens RA (2021) The price of success: immune-related adverse events from immunotherapy in lung cancer. Curr Oncol 28(6):4392–4407
Druel V, Gimenez L, Paricaud K, Delord J-P, Grosclaude P, Boussier N, Rouge Bugat M-E (2020) Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancer. BMC Cancer 20:495. https://doi.org/10.1186/s12885-020-06993-0
Elkhader J, Elemento O (2022) Artificial intelligence in oncology: from bench to clinic. Semin Cancer Biol 84:113–128
Gray S, Park E, Najita J et al (2016) Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med 18:1011–1019
Kaspers GJL (2022) 20 years of expert review of anticancer therapy. Expert Rev Anticancer Ther 22(1):1–2. https://doi.org/10.1080/14737140.2022.2019019
Luo X, Chen YZ, Chen J, Zhang Y, Li MF, Xiong CX, Yan (2022) Effectiveness of mobile health-based self-management interventions in breast cancer patients: a meta-analysis. Supp Care Cancer 30:2853–2876
Lwin Z, Broom A, Sibbritt D, Francis K, Karapetis CS, Karikios D, Harrup R (2018) The Australian medical oncologist workforce survey: the profile and challenges of medical oncology. Sem in Oncol 45(5–6):284–290
Mathew A (2018) Global survey of clinical oncology workforce. JCO Global Oncol 4:1–12
Mooney K, Titchener K, Haaland B, Coombs LA, O’Neil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021) Evaluation of oncology hospital at home: unplanned health care utilization and costs in the Huntsman at Home real-world trial. J Clin Oncol 39(23):2586–2593
Nefreteri S, Elmore C, Praijogi B, Polo Rubio JA, Zubizarreta E (2019) The global radiation oncology workforce in 2030: estimating physician training needs and proposing solutions to scale up capacity. Appl Rad Oncol, 9–16
Ngusie HS, Kassie SY, Chereka AA, Enyew (2022) Healthcare providers’ readiness for electronic health record adoption: a cross-sectional study during pre-implementation phase. BMC Heal Serv Res 22. https://doi.org/10.1186/s12913-022-07688-x
Nipp RD, Shulman E, Smith M, Brown PMC, Johnson PC, Gaufberg E, Vyas C, Qian CL, Neckermann I, Hornstein SB, Reynolds MJ, Green J, Temel JS, Areej E-J (2022) Supportive oncology care at home interventions: protocols for clinical trials to shift the paradigm of care for patients with cancer. BMC Cancer 22:383. https://doi.org/10.1186/s12885-022-09461-z
Noteboom EA, Perfors LAA, May AM, Stegmann ME, Duijts SFA, Visserman EA, Engelen V, Richel C, van der Wall E, de Wit N, Helsper CW (2021) GP involvement after a cancer diagnosis; patients’ call to improve decision support. BJGP Open 5(1). https://doi.org/10.3399/bjgpopen20X101124
Ohno-Machado L, Kim J, Gabriel RA, Kuo GM, Hogarth MA (2018) Genomics and electronic health record systems. Hum Mol Genet 27:R48–R55
Parikh RB, Teeple S, Navathe AS (2019) Addressing bias in artificial intelligence in health care. JAMA 322:2377–2378
Patt DA, Wilfong L, Toth S, Broussard S, Kanipe K, Hammonds J (2021) Telemedicine in community cancer care: how technology helps patients with cancer navigate a pandemic. JCO Oncol Pract 17(1):e11–e15
Penson A, Camacho N, Zheng Y et al (2020) Development of genome-derived tumor type prediction to inform clinical cancer care. JAMA Oncol 6:84–91
Rapoport B, Cooksley T, Johnson DB, Anderson R (2021) Supportive care for new cancer therapies. Curr Opin Oncol 33(4):287–294
Raza A (2019) The first cell: and the human costs of pursuing cancer to the last. Basic Books, New York
Roberts MC, Spees LP, Freedman AN, Klein WMP, Prabhu Das I, Butler EN, de Moor JS (2021) Oncologist-reported reasons for not ordering multimarker tumor panels: results from a nationally representative survey. JCO Prec Oncol 5:701–709
Shah C, Royce TJ (2021) Chicken little or goose is cooked.? the state of the US radiation oncology workforce: workforce concerns in US radiation oncology. Int J Rad Oncol Biol Phys 110(2):268–271
Shih Y-CT, Kim B, Halpern MT (2021) State of physician and pharmacist oncology workforce in the United States in 2019. JCO Oncol Pract 17(1):e1–e10
Sing S, Farrelly A, Chan C, Nicholls B, Nazeri-Rad N, Bellicoso D (2022) Prevalence and workplace drivers of burnout in cancer care physicians in Ontario, Canada. JCO Oncol Pract 18(1):e60–e71
Stefan DC (2015) Cancer care in Africa: an overview. JCO Global Oncol 1:30–3a
Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris HA III, Spigel DR, Hamilton EP, McKenzie AJ (2021) Next-generation sequencing of patients with breast cancer in community oncology clinics. JCO Prec Oncol 5:1297–1311
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
Wu CHD, Malik N, Kim M, Stuckless T, Halperin R, Archambault J, Thompson R, Ringash J, Brundage M, Loewen SK (2022) Employment outcomes for Canadian radiation oncology graduates: 2020 assessment and longitudinal trends. Adv Rad Oncol 7(3). https://doi.org/10.1016/j.adro.2022.100915
Yates M, Samuel V (2019) Burnout in oncologists and associated factors: a systematic literature review and meta-analysis. Eur J Cancer Care. https://doi.org/10.1111/ecc.13094
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
Conflict of Interest Disclosure
I, Fredrick Ashbury, disclose that my affiliation with VieCure, a company I have co-founded and invested in that operates within the oncology space. Aside from this, I have no personal, financial, or professional conflicts of interest. I certify that all my current and foreseeable conflicts of interest, or their absence, have been disclosed here.
I, Keith Thompson, disclose that my affiliation with VieCure, is a company I have invested in that operates with the oncology space. Aside from this, I have no personal, financial, or professional conflicts of interest. I certify that all my current and foreseeable conflicts of interest, or their absence, have been disclosed here.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ashbury, F.D., Thompson, K. (2023). Accelerating Personalized Medicine Adoption in Oncology: Challenges and Opportunities. In: Çetin, E., Özen, H. (eds) Healthcare Policy, Innovation and Digitalization. Accounting, Finance, Sustainability, Governance & Fraud: Theory and Application. Springer, Singapore. https://doi.org/10.1007/978-981-99-5964-8_4
Download citation
DOI: https://doi.org/10.1007/978-981-99-5964-8_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-5963-1
Online ISBN: 978-981-99-5964-8
eBook Packages: Business and ManagementBusiness and Management (R0)